News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No significant news items were published in the past hour.
  • US and European markets had no fresh catalysts reported this hour.
  • Bond and FX markets showed little headline-driven volatility over the past hour.
  • No central bank statements or economic data were released in the past hour.
  • No new geopolitical incidents or major policy announcements emerged this hour.
  • Trading liquidity and risk sentiment were unchanged amid the quiet news flow.

Latest Articles

The XFLT Proxy Contest: What XFLT Shareholders Need to Know

The XFLT Proxy Contest: What XFLT Shareholders Need to Know

XAI Floating Rate & Alternative Income Trust (XFLT) announced a shareholder vote on July 30, 2026, to approve a new sub-advisory agreement with Rockford Tower Asset Management, a King Street Capital Management subsidiary. This change follows termination of previous sub-adviser Octagon due to significant underperformance. The Board anticipates impro…

Bempikibart Momentum: A Tactical Long on Q32 Bio (QTTB)

Bempikibart Momentum: A Tactical Long on Q32 Bio (QTTB)

Q32 Bio's recent program developments and corporate actions have shifted the risk profile from pure early-stage binary to one with tangible commercial optionality and cash support. I outline a mid-term trade plan that captures upside to program re-rating while limiting downside with a defined stop.

VisionWave Files Provisional Patent Application for GhostSight™, a Hybrid Passive Radar Architecture Using Intelligent Cooperative Illumination

VisionWave Files Provisional Patent Application for GhostSight™, a Hybrid Passive Radar Architecture Using Intelligent Cooperative Illumination

VisionWave Holdings announces filing of a provisional patent application for GhostSight™, a hybrid passive radar system that combines environmental RF signals with distributed cooperative illuminators, enhanced by AI/ML fusion for improved detection, classification, and situational awareness across defense and security sectors.

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Amneal Pharmaceuticals has obtained FDA approval for new strengths and vial sizes of its iohexol injection, a radiographic contrast agent used in various imaging procedures. The expanded portfolio is set to meet most of the U.S. iohexol injection market demand, positioning Amneal as a key player in complex injectables and hospital products. The com…

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Therapeutics, a biotechnology company focused on treatments for blood disorders, announced its redomestication from Delaware to the Cayman Islands effective July 16, 2026. The company's shares will continue to trade on Nasdaq under the symbol DMRA with a new CUSIP. The redomestication does not change the company's operations or management.

Abacus Global Management to Announce Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Abacus Global Management to Announce Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Abacus Global Management, a NYSE-listed financial services firm specializing in alternative asset management, announced it will release its Q2 2026 financial results after market close on August 6, 2026. The company will host a conference call and webcast to discuss the results the same day, providing investors with an opportunity to engage and ass…

NANO Nuclear Energy Joins Virginia Nuclear Energy Consortium to Advance Nuclear Innovation and Support the Commonwealth’s Growing Energy Requirements

NANO Nuclear Energy Joins Virginia Nuclear Energy Consortium to Advance Nuclear Innovation and Support the Commonwealth’s Growing Energy Requirements

NANO Nuclear Energy Inc. (NASDAQ: NNE) has joined the Virginia Nuclear Energy Consortium (VNEC) to collaborate on advancing nuclear energy innovation, deployment, research, and workforce initiatives in Virginia, a state experiencing rapid growth in power demand, especially from data centers. As a part of VNEC, NANO Nuclear aims to leverage Virginia…

General Fusion to Ring Nasdaq Opening Bell Today, July 17, 2026

General Fusion to Ring Nasdaq Opening Bell Today, July 17, 2026

General Fusion Group Ltd. announced its recent listing on Nasdaq under the ticker GFUZ and its celebration ringing the Nasdaq Opening Bell, marking it as the first publicly listed fusion energy company. The company highlighted its Magnetized Target Fusion (MTF) technology and the development of its LM26 fusion demonstration machine, aiming to achie…

Nano Dimension Continues Execution of Cost Savings Initiatives

Nano Dimension Continues Execution of Cost Savings Initiatives

Nano Dimension Ltd. announced the termination of its corporate headquarters lease, originally set to expire in 2031, resulting in approximately $25 million net cash savings after lease termination payment. This move is part of broader cost-saving initiatives following the sale of MarkForged, aiming to strengthen the company's financial position by …

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SL Science Holding Limited announced successful presentation of preclinical data demonstrating the potent anti-glioblastoma effects of their novel gamma delta T-cell therapy at the 2026 World Congress of Basic and Clinical Pharmacology. The research, conducted in collaboration with Taipei Medical University, JY BioMed, and HeXun Biosciences, showed…

Upgrade: Grindr's Paid-User Momentum Justifies a Swing Long

Upgrade: Grindr's Paid-User Momentum Justifies a Swing Long

Grindr is showing durable paid-user strength and profitable growth that the market is under-appreciating. With revenue up ~28% y/y to $440M in 2025 and net income returning to $95M, the stock at $15.76 is offering asymmetric upside toward $20 while still managing meaningful downside risk from leverage and governance noise. We upgrade the rating and…

FedEx Freight: Buy the Early Recovery While Capacity Is Spare

FedEx Freight: Buy the Early Recovery While Capacity Is Spare

FedEx's freight unit sits with spare capacity while overall freight demand shows signs of recovery. At $318, the stock trades at ~17x earnings with solid free cash flow and room for margin recovery if pricing normalizes. This trade targets a re-test of the $345 area over the next 45 trading days with a disciplined stop below $298.

Wakefern and ShopRite Expand Edible Garden’s Successful “Garden Starters” Program with Midsummer Promotion

Wakefern and ShopRite Expand Edible Garden’s Successful “Garden Starters” Program with Midsummer Promotion

Edible Garden AG Incorporated announced that Wakefern Food Corp. is expanding the Garden Starters pallet display program with a midsummer promotional event at participating ShopRite locations. The program features USDA Organic Certified living herb plants to meet rising consumer demand for fresh, sustainable produce and promote home gardening. Edib…

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

Clearmind Medicine Inc., trading as CMND on Nasdaq, applauds recent developments by multiple U.S. federal agencies including FDA, HHS, VA and others, which support the advancement of psychedelic-based therapies for neuropsychiatric and addiction disorders. The company highlights regulatory progress such as final FDA guidance on psychedelic clinical…

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion A/S will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 at the upcoming ESMO Congress 2026. The data includes insights on EVX-01's durability and effectiveness as a stand-alone treatment for advanced melanoma. Previous two-year results showed high response rates and sustained immune re…